The contribution of vaccine manufacturers to the establishment of vaccination policies

Journal of Public Health

Volumn 16, Issue 4, 2008, Pages 299-305

  Hessel, Luc ^a  

^a SANOFI PASTEUR   (France)

Author keywords

Pharmaceutical industry; Vaccination policies; Vaccine

Indexed keywords

VACCINE;

COOPERATION; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG EFFICACY; DRUG INDUSTRY; DRUG INFORMATION; DRUG MARKETING; DRUG SAFETY; FOLLOW UP; HEALTH CARE POLICY; IMMUNIZATION; INVESTMENT; OUTCOMES RESEARCH; RESPONSIBILITY; REVIEW; RISK MANAGEMENT; VACCINATION;

EID: 48149093139     PISSN: 09431853     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10389-008-0202-0     Document Type: Review

References (22)

1. P Arveux S Bénard S Bouée A Lafuma L Martin L Cravello V Rémy JG Breugelmans 2007 [Invasive cervical cancer treatment costs in France]-Coût de la prise en charge du cancer invasif du col de l'utérus en France Bull Cancer 94 2 219 224
2. C Bergeron JG Breugelmans S Bouée C Lorans S Bénard V Rémy 2006 [Cervical cancer screening and associated treatment costs in France]-Coût du dépistage et de la prise en charge des lésions précancéreuses du col utérin en France Gynecol Obstet Fertil 34 1036 1042
3. C Bergeron N Largeron R McAllister P Mathevet V Rémy 2008 Cost-effectiveness analysis of the introduction of a quadrivalent human-papillomavirus vaccine in France Int J Technol Assess Health Care 24 1 10 19
4. Canada Communicable Disease Report (2007) The process to establish and implement national goals and recommendations for vaccine preventable diseases in Canada under the national immunization strategy. December 1, 33:13
5. Commission Fédérale pour les Vaccinations (CFV) and Office fédéral de la santé publique (OFSP) 2005 Swiss Federal Advisory Committee on Immunisations and Swiss Federal Agency for Public Health, Vaccination, Recommendations in Switzerland: Categories of recommendation. Recommandations de vaccination en Suisse: niveaux de Recommandation Bulletin Bundesamt für Gesundheit (BAG) 45 817 821
6. EH Elbasha EJ Dasbach RP Insiga 2007 Model for Assessing Human Papillomavirus Vaccination Strategies Emerging Infect Dis 13 1 28 41
7. GL Freed 2007 Lessons from across the pond: What the US can learn from European immunization programs Vaccine 25 33 6148 6157
8. C Giaquinto P Van Damme F Huet L Gothefors M Van der Wielen 2007 Costs of community-acquired pediatric rotavirus gastroenteritis in 7 European countries: The REVEAL Study J Infect Dis 195 Suppl 1 S36 S44
9. C Giaquinto P Van Damme F Huet L Gothefors M Maxwell P Todd L da Dalt 2007 Clinical Consequences of Rotavirus Acute Gastroenteritis in Europe, 2004-2005: The REVEAL Study J Infect Dis 195 Suppl 1 S26 S35
10. L Hessel 2005 Risk Management, Vaccines and Vaccination Screening 4 18 20
11. H Kalies V Grote T Verstraeten L Hessel HJ Schmitt R von Kries 2006 The use of combination vaccines has improved timeliness of vaccination in children Pediatr Infect Dis J 25 6 507 512
12. Kruger Kjaer S, Breugelmans JG, Munk C, Watson M, Iftner T (2006) HPV prevalence and type distribution in Denmark: The Cleopatre study. 6th International Multidisciplinary Congress - European Research Organization on Genital Infection and Neoplasia (EUROGIN). Paris, France, April 23-26, (Abstract)
13. J Monsonego JG Breugelmans S Bouée A Lafuma S Bénard V Rémy 2007 [Anogenital warts incidence, medical management and costs in women consulting gynaecologists in France] - Incidence, prise en charge et coût des condylomes acuminés anogénitaux chez les femmes consultant leur gynécologue en France Gynecol Obstet Fertil 35 2 107 113
14. Nohynek H (2008) The decision-making process to recommend a new vaccine. From vaccine research to policy and programme implementation - the Finnish experience. J Public Health (in press)
15. P Olin L Gustafsson L Barreto L Hessel TC Mast A van Rie H Bogaerts J Storsaeter 2003 Declining pertussis incidence in Sweden following the introduction of acellular pertussis vaccine Vaccine 21 17/18 2024 2030
16. Postma MJ (2008) Public Health Economics of Vaccines in the Netherlands methodological issues and applications. J Public Health (in press)
17. Siegrist CA, Balinska MA (2008) The public perception of the value of vaccines. J Public Health (in press)
18. BA Van der Zeijst MI Dijkman W Luytjes AJW van Alphen GPJM van den Dobbelsteen 2007 On the design of national vaccination programmes Vaccine 25 16 3143 3145
19. Velasco-Garrido M, Busse R (2005) Health Technology Assessment - An Introduction to objectives, role of evidence and structure in Europe. European Observatory on Health Systems and Policies, available on http://www.eunethta. net/HTA/HTA_Networks/ - last accessed February 2008
20. I Vergote AGJ van Der Zee V Kesic B Sert H Robova L Rob N Reed DM Luesley E Leblanc B Hagen G Gitsch A Du Bois G Di Vagno N Colombo U Beller A Ayhan I Jacobs 2007 ESGO statement on cervical cancer vaccination Int J Gynecol Cancer 17 6 1183 1185
21. Vesikari T (2008) The role of scientific societies in the decision-making process to recommend new vaccines: the example of rotavirus in Europe. J Public Health (in press)
22. MK Wynia 2007 Public health, public trust and lobbying Am J Bioeth 7 6 4 7